Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virology

Human Immunodeficiency Virus and Leprosy Coinfection in Pune, India

Kulkarni Vinay, Joshi Smita, Gupte Nikhil, Gokhale Neeta
Kulkarni Vinay
1PRAYAS, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshi Smita
2Hirabai Cowasji Jehangir Medical Research Institute, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: smitanjoshi@gmail.com
Gupte Nikhil
3B. J. Medical College CTU, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gokhale Neeta
1PRAYAS, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00876-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We report eight cases and the incidence of leprosy in human immunodeficiency virus (HIV)-infected individuals after initiation of antiretroviral treatment (ART). The incidence of leprosy in patients on ART was 5.22 per 1,000 person-years (95% confidence interval, 2.25 to 10.28). This high incidence suggests that there should be regular examination of HIV-infected individuals for clinical signs of leprosy.

Although there is a declining trend in the global burden of leprosy, there are 15 countries in Asia and Africa which account for 94% of the global total of the new-case detection rate. India is one of the countries where ≥1,000 new cases of leprosy were reported during 2006 (14). Human immunodeficiency virus (HIV) and leprosy both are feared due to the associated social stigma, and leprosy can manifest as immune reconstitution inflammatory syndrome (IRIS) in HIV-infected individuals (9). The first case of leprosy-associated immune reconstitution disease was reported in 2003 for a Ugandan living in London, United Kingdom (5). Later leprosy was described as a manifestation of IRIS in many instances (8, 10).

Antiretroviral treatment (ART) for HIV infection is now available in resource-poor regions where leprosy is still endemic, such as South America, Africa, and Asia, including India. India accounts for half of the world's leprosy cases due to its population of more than 1 billion, even though a nationwide prevalence of less than 1 case/10,000 population was reported in 2005 (4). In addition, India also has the third largest burden of HIV-infected individuals (12). In spite of having a large burden of both leprosy and HIV, there are very few published reports of HIV-leprosy coinfection from India. We report eight cases of incident leprosy in HIV-infected patients who were on ART and the incidence of leprosy in HIV-infected individuals on ART.

This report is from the Amrita Clinic of PRAYAS, a nongovernmental organization working on HIV/AIDS in Pune, in the state of Maharashtra, India. We retrospectively analyzed data on HIV-infected patients who initiated ART between January 2003 and December 2006 and we studied their follow-up till December 2007 to evaluate the incident cases of leprosy. ART was provided following the national guidelines for treatment of HIV infection (7).

Diagnosis of leprosy was based on the clinical signs and symptoms and demonstration of acid-fast bacilli in the slit skin smears by Ziehl-Neelsen staining. All patients with leprosy received multidrug treatment per the WHO guidelines (15).

Several definitions of IRIS have been utilized, each incorporating the general concept that cases of IRIS need to have an inflammatory component occurring in the setting of immune reconstitution that cannot be explained by drug toxicity or a new opportunistic infection (1, 6). We have considered leprosy manifestation after starting ART with increase in CD4+ cell count, inflammatory response as seen by neuritis, type I or type II leprosy reaction, or need for the use of steroids for the control of inflammation as a criterion for defining leprosy manifestation as IRIS. Statistical analysis was done using STATA (version 8.0).

Between January 2003 and December 2006, among the 1,002 HIV-infected patients who started ART for HIV infection and were followed up till December 2007, eight incident cases of leprosy were detected. None of them had clinical evidence of leprosy at the time of initiation of ART. Table 1 describes the details of these eight patients. All the patients except for one were males, and the mean age of the patients with leprosy was 33.8 years (standard deviation [SD], 5.1 years; range, 27 to 42 years). Four patients had paucibacillary leprosy, and four patients had multibacillary leprosy. The mean CD4+ cell count of incident leprosy cases was 326 (median, 245; SD, 255.5; range, 99 to 892). Of these eight patients, three had other opportunistic infections such as pulmonary tuberculosis, abdominal tuberculosis, and herpes zoster. The mean number of months to develop leprosy after starting ART was 13.8 months (SD, 14.3 months; range, 2 to 43 months). All eight patients completed their leprosy treatment and recovered completely. Although eight patients developed incident leprosy, six of them developed leprosy within 2 years of starting ART and two patients had delayed manifestations, with one patient developing leprosy after 28 months and the other after 43 months. These 1,002 patients on ART contributed to 1,532.5 person-years, and hence, the overall incidence of leprosy after starting ART was 5.22 per 1,000 person-years (95% confidence interval, 2.25 to 10.28).

To our knowledge, this is the first published report on the incidence of leprosy in HIV-infected patients on ART. ART is now more accessible in resource-poor regions where leprosy is still endemic, and reports of leprosy associated with immune reconstitution disease are increasing. This disease is most likely to be seen in India, where the HIV epidemic is growing and where 161,457 new cases of leprosy were diagnosed in 2005 alone (2). Vigilance needs to be especially high during the first several months of therapy, when the incidences of IRIS peaks, but cases continue to occur even after 1 or 2 years of therapy. Leprosy may not always manifest as IRIS, and there are a few reports of leprosy-HIV coinfection among patients who were not receiving ART (11). Difficulty in defining IRIS has been reported elsewhere (13), and we have faced similar difficulty in labeling two cases of leprosy as IRIS that developed at 28 and 43 months, respectively, after initiating ART. It is not clear if it was due to immune reconstitution or new infection, and prospective well-planned studies with longer follow-up will help in identifying the longest interval to development of IRIS.

Our report shows a high incidence of leprosy in HIV-infected individuals after initiation of ART. In the same state of Maharashtra, in the general population, the National Leprosy Elimination Programme reported a total of 12,397 new cases of leprosy and the new case detection rate was 11.12 per 100,000 with the prevalence being 0.71 per 10,000 population (3).

To conclude, with the availability of ART in developing countries, more and more incident leprosy cases are likely to be seen in areas where leprosy is endemic and HIV is also highly prevalent. HIV-infected individuals on ART from countries where leprosy is endemic should be regularly examined for cutaneous lesions and nerve thickness, especially during the first 2 years of starting ART, but cases may continue to occur even after 1 to 2 years of therapy.

View this table:
  • View inline
  • View popup
TABLE 1.

Details of HIV-infected patients on ART with incident leprosya

FOOTNOTES

    • Received 2 May 2009.
    • Returned for modification 10 June 2009.
    • Accepted 18 June 2009.
  • Copyright © 2009 American Society for Microbiology

REFERENCES

  1. 1.↵
    Breton, G., X. Duval, C. Estellat, et al. 2004. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin. Infect. Dis.39:1709-1712.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Couppié, P., S. Abel, H. Voinchet, et al. 2004. Immune reconstitution inflammatory syndromes associated with HIV and leprosy. Arch. Dermatol.140:997-1000.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Government of India. March 2008. National Leprosy Elimination Programme report. Ministry of Health and Family Welfare, Government of India, New Delhi, India.
  4. 4.↵
    Jacob, J. T., and C. Franco-Paredes. 2008. The stigmatization of leprosy in India and its impact on future approaches to elimination and control. PLoS Negl. Trop. Dis.2(1):ze113.
    OpenUrl
  5. 5.↵
    Lawn, S. D., C. Wood, and D. N. Lockwood. 2003. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin. Infect. Dis.36:e5-e6.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Lortholary, O., A. Fontanet, N. Memain, et al. 2005. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS19:1043-1049.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    National AIDS Control Organisation. 29 August 2007, posting date. Antiretroviral therapy guidelines for HIV infected adults and adolescents including post-exposure. National AIDS Control Organisation, Ministry of Health and Family Welfare, Government of India, New Delhi, India. http://www.nacoonline.org/Quick_Links/Publication/ .
  8. 8.↵
    Pignataro, P., A. S. Rocha, J. A. Nery, et al. 2004. Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis.23:408-411.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Shelburne, S. A., III, and R. J. Hamill. 2003. The immune reconstitution inflammatory syndrome. AIDS Rev.5:67-79.
    OpenUrlPubMed
  10. 10.↵
    Talhari, C., P. R. L. Machado, L. C. Ferreira, and S. Talhari. 2007. Shifting of the clinical spectrum of leprosy in an HIV-positive patient: a manifestation of immune reconstitution inflammatory syndrome. Lepr. Rev.78:151-154.
    OpenUrlPubMedWeb of Science
  11. 11.↵
    Trindade, M. A., N. Y. Valente, M. I. Manini, M. D. Takahashi, C. F. Anjos, G. Benard, and B. Naafs. 2006. Two patients coinfected with Mycobacterium leprae and human immunodeficiency virus type 1 and naive for antiretroviral therapy who exhibited type 1 leprosy reactions mimicking the immune reconstitution inflammatory syndrome. J. Clin. Microbiol.44:4616-4618.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    UNAIDS. December 2007. AIDS epidemic update. UNAIDS. http://data.unaids.org/pub/EPISlides/2007/071119_epi_pressrelease_en.pdf . Accessed 13 March 2008.
  13. 13.↵
    Visco-Comandini, U., B. Longo, T. Cuzzi, M. G. Paglia, and G. Antonucci. 2004. Tuberculoid leprosy in a patient with AIDS: a manifestation of immune restoration syndrome. Scand. J. Infect. Dis.36:881-883.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Weekly Epidemiological Record. 2007. Global leprosy situation. Wkly. Epidemiol. Rec.82:225-232.
    OpenUrlPubMed
  15. 15.↵
    World Health Organization. 22 December 2006, last update. Leprosy tools and guidelines. World Health Organization, Geneva, Switzerland. http://www.searo.who.int/EN/Section10/Section20/Section57_9882.htm .
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Human Immunodeficiency Virus and Leprosy Coinfection in Pune, India
Kulkarni Vinay, Joshi Smita, Gupte Nikhil, Gokhale Neeta
Journal of Clinical Microbiology Aug 2009, 47 (9) 2998-2999; DOI: 10.1128/JCM.00876-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Immunodeficiency Virus and Leprosy Coinfection in Pune, India
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Human Immunodeficiency Virus and Leprosy Coinfection in Pune, India
Kulkarni Vinay, Joshi Smita, Gupte Nikhil, Gokhale Neeta
Journal of Clinical Microbiology Aug 2009, 47 (9) 2998-2999; DOI: 10.1128/JCM.00876-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

HIV Infections
leprosy

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X